Ulteriori informazioni
Discoveries in Pharmacology: Volume 1: Nervous system and hormones (2nd Ed.) presents selected articles from the historic Discoveries in Pharmacology series enhanced with commentary from contemporary scholars about the reception and importance of the chapter along with an updated bibliography on the subject with contributions from a Nobel Prize winner and other pioneers in Pharmacology. The Discoveries in Pharmacology series brought acknowledged experts in their fields together to provide first-hand accounts of important pharmacological discoveries discussing the scientific background and stories behind these pivotal moments. They allow a true understanding of the means by which pharmacological discoveries are made. This volume brings forth discussions on key discoveries in psycho- and neuro-pharmacology, haemodynamics, and hormones including chapters on antipsychotic agents by Nobel winner Anders Carlsson, Willy Haefely on benzodiazepine, and butyrophenone-type neuroleptics by P. A. J. Janssen and J. P. Tollenaere. Academic and industry researchers in pharmacology and medicine, as well as advanced students in the area will find this series a useful teaching tool and launch to new discoveries. Chapters can also be used to supplement course material in pharmacology and medical courses. It will also be of interest to those who are interested in the history of medicine.
Sommario
1. Chemical transmission of nerve impulses
2. The suppression of psychotic behaviour: Discovery of the clinical use of neuroleptics
3. The suppression of psychotic behaviour: The discovery of the butyrophenone-type neuroleptics
4. The suppression of psychotic behaviour: Antipsychotic agents: elucidation of their mode of action
5. Antidepressants: Clinical discoveries with antidepressant drugs
6. Antidepressants: Monoamine oxdase and its inhibitors in relation to antidepressive activity
7. Levodopa and dopamine agonists in the treatment of Parkinson's disease
8. Alleviation of anxiety
9. The development of antiepileptic drugs
Info autore
Professor Clive P. Page, BSc PhD OBE HonFBPhS is a Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of and on boards of several companies. He was awarded the Society of Biology President’s Medal in 2012 for an outstanding contribution to the life sciences over the previous year. He is a Fellow of the Royal Society of Biology and an Honorary Fellow and President Elect of the British Pharmacological Society. In 2017, Clive was awarded an OBE for Services to Pharmacology.Professor Jacques Bruinvels, Ph.D. is Professor Emeritus of Pharmacology, Department of Pharmacology, Erasmus University Rotterdam, Rotterdam, The Netherlands. Full biography to followProfessor Michael J. Parnham, Ph.D., C.Biol.MRSB, FBPhS studied Pharmacology at Chelsea (now King's) College, gaining practical experience in the department of the subsequent Nobel Prize winner, John R. Vane, at the Royal College of Surgeons. With a PhD from Bristol University (1976), he carried out postdoctoral research on prostaglandins and chronic inflammation with Ivan Bonta at Erasmus University Rotterdam, The Netherlands. He established laboratories in pharmacology and toxicology and was Director of Preclinical Discovery working on novel anti-inflammatory macrolides at GSK from 2006. From 2012 to 2019, Prof. Parnham built up preclinical research in the Fraunhofer Institute of Molecular Biology & Applied Ecology IME. Dr. Parnham has published and lectured extensively and organised symposia on various aspects of immunopharmacology and anti-inflammatory therapy and in 2015, received a Lifetime Achievement Award from the International Association of Inflammatory Societies (IAIS). He is a scientific advisor to several companies.
